Abstract
From the data presented, it would appear that PiZ subjects who develop clinically significant airflow limitation go through a phase of their disease in which there is a relatively high rate of functional decline. This is encouraging in regard to the feasibility of a trial of antiprotease therapy. It suggests that beneficial effects of such therapy could be demonstrated by showing a reduction in the rate of loss of function in subjects properly selected for such a clinical trial.
Original language | English (US) |
---|---|
Pages (from-to) | S43-S45 |
Journal | American Review of Respiratory Disease |
Volume | 127 |
Issue number | 2 |
State | Published - 1983 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine